If you have been reading about bremelanotide and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-05-18. Where a claim depends on a specific study, the study is described rather than over-claimed.
Development of the peptide passed through several delivery formats, including an intranasal version tested in early trials and an injectable version that entered later clinical study. Regulatory approval for a subcutaneous product in the United States was granted in 2019 after review of controlled trials in premenopausal women. Outside the clinic, the compound circulates in research and non-pharmaceutical markets under its code name, where identity and purity vary considerably between suppliers. Synonyms appearing across technical literature include bremelanotide, PT-141, and Palatin 141.
PT-141 is the research designation for bremelanotide, a synthetic cyclic heptapeptide developed as a melanocortin receptor agonist. The peptide contains seven amino acids with an internal lactam bridge that constrains the backbone into a stable ring. Cyclisation of this kind improves resistance to enzymatic degradation relative to linear analogues. The compound was first explored for effects on melanin production, because several melanocortin receptors influence pigmentation. Its later association with sexual desire emerged from observations made during that early work, and the molecule became the subject of a separate development programme.
Bremelanotide is a moderately large peptide with a molecular mass near 1025 daltons. In lyophilised form it appears as a white to off-white powder and is freely soluble in water and other polar solvents. The intact lactam ring is essential for receptor affinity, while linearised fragments bind far more weakly. Solutions are sensitive to extremes of pH and to prolonged exposure to light and heat, so handling typically involves buffered conditions and cold storage. Its short plasma half-life reflects rapid distribution and clearance rather than chemical breakdown inside the vial.
Regulatory review of bremelanotide concluded in 2019 with approval in the United States for a defined indication in premenopausal women. The reviewed formulation is a single-use prefilled autoinjector given subcutaneously, and its label carries cardiovascular monitoring language tied to blood pressure changes recorded during trials. Availability outside the approving jurisdiction varies, and in several countries the compound remains unapproved or is handled as a prescription-only item. Compounded and research-grade material also circulates, and it differs from the reviewed product in purity, characterization, and chain of custody.
Bremelanotide is a synthetic cyclic heptapeptide developed under the research code PT-141. The code reflects its position in an internal compound series rather than a chemical classification, and the name bremelanotide was later adopted for regulatory filings. Structurally it belongs to the melanocortin peptide family and shares a core sequence motif with alpha-melanocyte-stimulating hormone. The compound is supplied as an acetate salt in aqueous solution for injection. In reference literature it is indexed under both the code and the generic name, a dual listing that can complicate database searches.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Cyclic heptapeptide | Synthetic melanocortin analogue |
| Molecular formula | C50H68N14O10 | Corresponds to a mass near 1025 daltons |
| Appearance | White to off-white powder | Lyophilised solid before reconstitution |
| Solubility | Soluble in water and polar solvents | Poor solubility in nonpolar media |
| Common synonyms | Bremelanotide, PT-141 | Code name and international name used interchangeably |
The compound emerged from a research programme examining melanocortin analogues for effects on skin pigmentation. During early human studies, participants reported spontaneous erections as an unexpected side effect, which redirected development toward sexual function rather than tanning. An intranasal formulation was investigated in clinical trials but did not reach market approval. A subcutaneous injectable version later completed the regulatory process, and the nasal route does not appear in approved labelling.
Approved use is narrow and jurisdiction-specific. In the United States, the injectable product is authorised for premenopausal women with acquired, generalised hypoactive sexual desire disorder, a diagnosis that requires documented distress. It is not approved for men, for postmenopausal women, or for use alongside hormonal contraceptives under the approved labelling. Outside regulated markets, the same peptide is frequently sold as a research chemical, where identity, purity, and sterility are not independently verified.
Bremelanotide is a synthetic cyclic heptapeptide developed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation and appetite signalling. Its structure contains seven amino acid residues joined by a lactam bridge that closes the ring between two side chains. The molecular formula is C50H68N14O10 and the nominal molecular mass is near 1025 daltons. Much of the early laboratory literature refers to the same molecule by the development code PT-141.
Development began with intranasal formulations investigated for erectile dysfunction, but blood pressure elevation limited that route and prompted a switch to subcutaneous delivery. Clinical testing then shifted toward hypoactive sexual desire disorder in premenopausal women, and a subcutaneous product received United States approval in 2019. Later trials examined other populations with mixed results, and questions about effect size, durability and patient selection remain open in the peer-reviewed literature. Research interest continues in parallel with the broader melanocortin field, where several synthetic analogues are studied together.
PT-141 is the research code for bremelanotide, a cyclic heptapeptide derived from alpha-melanocyte-stimulating hormone. The molecule belongs to the melanocortin receptor agonist family and shows highest affinity for the MC4 receptor subtype, with weaker activity at MC1, MC3 and MC5. Its structure retains the core His-Phe-Arg-Trp sequence that defines melanocortin recognition, while cyclization and terminal modifications improve metabolic stability relative to the parent hormone. Early work classified the compound as a centrally acting agent rather than a peripherally acting vasodilator, which shaped subsequent development priorities.
=== Genomes === Genomic DNA is tightly and orderly packed in the process called DNA condensation, to fit the small available volumes of the cell. In eukaryotes, DNA is located in the cell nucleus, with small amounts in mitochondria and chloroplasts. In prokaryotes, the DNA is held within an irregularly shaped body in the cytoplasm called the nucleoid. The functional genetic information in a genome is located in genes, regulatory sequences, origins of replication, centromeres, telomeres, and segments required for the three-dimensional structure of chromatin. In many complex eukaryotes, only a small fraction of the total sequence is devoted to the various functional elements. For example, in humans less than 10% of the genome has a defined functional role and the rest (90%) is probably junk DNA. (See also [Non-coding DNA].)
=== COVID-19 === In 2020, the monoclonal antibody therapies bamlanivimab/etesevimab and casirivimab/imdevimab were given emergency use authorizations by the US Food and Drug Administration to reduce the number of hospitalizations, emergency room visits, and deaths because of COVID-19. In September 2021, the Biden administration purchased US$2.9 billion worth of Regeneron monoclonal antibodies at $2,100 per dose to curb the shortage. As of December 2021, in vitro neutralization tests indicate monoclonal antibody therapies (with the exception of sotrovimab and tixagevimab/cilgavimab) were not likely to be active against the Omicron variant. Over 2021–22, two Cochrane reviews found insufficient evidence for using neutralizing monoclonal antibodies to treat COVID-19 infections. The reviews applied only to people who were unvaccinated against COVID‐19, and only to the COVID-19 variants existing during the studies, not to newer variants, such as Omicron. In March 2024, pemivibart, a monoclonal antibody drug, received an emergency use authorization from the US FDA for use as pre-exposure prophylaxis to protect certain moderately to severely immunocompromised individuals against COVID-19.
Subsequently, ADP-actin dissociates slowly from the pointed end, a process significantly accelerated by the actin-binding protein, cofilin. ADP bound cofilin severs ADP-rich regions nearest the (−)-ends. Upon release, the free actin monomer slowly dissociates from ADP, which in turn rapidly binds to the free ATP diffusing in the cytosol, thereby forming the ATP-actin monomeric units needed for further barbed-end filament elongation. This rapid turnover is important for the cell's movement. End-capping proteins such as CapZ prevent the addition or loss of monomers at the filament end where actin turnover is unfavorable, such as in the muscle apparatus. Actin polymerization together with capping proteins were recently used to control the 3-dimensional growth of protein filament so as to perform 3D topologies useful in technology and the making of electrical interconnect. Electrical conductivity is obtained by metallisation of the protein 3D structure.
He visited Vedagiriswarar Temple where he had a conversation with a local expert about the symbols and sculptures on the gopuram of this temple. He later wrote about this conversation in his book Aion. Jung became ill on this trip, suffering delirium in a Calcutta hospital. After 1938, his travels were confined to Europe.
== Posthumous recognition == In 1959 she became the first woman elected to the Poultry Historical Society Hall of Fame. She was inducted into the National Women's Hall of Fame in 2002, the American Society of Heating, Refrigerating and Air-Conditioning Engineers Hall of Fame in 2007, and the National Inventors Hall of Fame in 2018.
Sources: en.wikipedia.org
Therefore, a large profit potential exists for the manufacturers and suppliers of processed food products. Individuals may see a benefit in convenience, but rarely see any direct financial cost benefit in using processed food as compared to home preparation. Processed food freed people from the large amount of time involved in preparing and cooking "natural" unprocessed foods. The increase in free time allows people much more choice in life style than previously allowed. In many families the adults are working away from home and therefore there is little time for the preparation of food based on fresh ingredients. The food industry offers products that fulfill many different needs: e.g. fully prepared ready meals that can be heated up in the microwave oven within a few minutes. Modern food processing also improves the quality of life for people with allergies, diabetics, and other people who cannot consume some common food elements. Food processing can also add extra nutrients such as vitamins.
===== MeSH D08.811.520.650 – phosphorus-oxygen lyases (EC 4.6) ===== MeSH D08.811.520.650.200 – adenylate cyclase MeSH D08.811.520.650.200.040 – adenylate cyclase toxin MeSH D08.811.520.650.600 – guanylate cyclase MeSH D08.811.520.650.600.500 – receptors, guanylate cyclase-coupled MeSH D08.811.520.650.600.500.500 – receptors, atrial natriuretic factor MeSH D08.811.520.650.800 – phosphatidylinositol diacylglycerol-lyase
=== Robin Williamson === Robin Williamson (Jonjo O'Neill) is the chief communications officer at Tender, assisting Whitney in pivoting the company into banking. During the launch of Tender's banking app, Robin clashes with Yasmin over their dueling PR strategies, with Robin preferring a more traditional rollout via tech publications and podcasts, while Yasmin seeks to capitalize on Henry Muck's profile as CEO by booking him a keynote speech. Yasmin's approach wins over Whitney, who promotes Yasmin to head of communications and fires Robin, deeming him too traditional and risk-averse.
=== Beer–Lambert law === The roots of the term absorbance are in the Beer–Lambert law (or Beer's law). As light moves through a medium, it will become dimmer as it is being "extinguished". Pierre Bouguer recognized that this extinction (now often called attenuation) was not linear with distance traveled through the medium, but related to what is now referred to as an exponential function. If
Sources: en.wikipedia.org
PT-141 is a laboratory code for bremelanotide, a synthetic peptide that activates melanocortin receptors. It has been developed both as an injectable pharmaceutical product and as a research chemical. The two contexts differ sharply in how identity, purity, and dosing are controlled.
It is neither a steroid nor a naturally occurring human hormone. Bremelanotide is a manufactured peptide that mimics part of the melanocortin signalling system by binding receptor proteins. Its effects come from receptor activation, not from replacing a circulating hormone.
The internal lactam bridge locks the peptide into a defined shape, which raises receptor affinity and slows enzymatic breakdown. Linear versions of the same sequence are less stable and bind more weakly. Ring geometry is therefore central to how the molecule behaves in the body.
PT-141 was the internal development code assigned to bremelanotide during preclinical research. Reference sources sometimes index the peptide under the code rather than the generic name. The two terms describe the same molecule.